Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that
its finance subsidiary Teva Pharmaceutical Finance Company, LLC has
called for redemption its approximately $500 million outstanding
principal amount of 5.550% Senior Notes due 2016 (CUSIP No. 88163V AC3).
The redemption is being funded with cash on hand.
The redemption date will be March 22, 2013, and the redemption price
will equal the principal amount of the notes plus a make whole premium
calculated in accordance with the terms of the applicable indenture. On
the redemption date, the redemption price, together with accrued and
unpaid interest from February 1, 2013, to, but excluding, the redemption
date, will become due and payable on the notes.
Details concerning the redemption price and the other terms and
conditions of the redemption will be more fully described in a Notice of
Redemption being provided to registered holders of the notes by The Bank
of New York Mellon, as trustee. Holders of notes who have questions
should contact Joellen McNamara of The Bank of New York Mellon at
1-212-815-5587 or via email at email@example.com,
or Teva's investor relations department at (215) 591-8912 or (011)
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global
pharmaceutical company, committed to increasing access to high-quality
healthcare by developing, producing and marketing affordable generic
drugs as well as innovative and specialty pharmaceuticals and active
pharmaceutical ingredients. Headquartered in Israel, Teva is the world's
leading generic drug maker, with a global product portfolio of more than
1,000 molecules and a direct presence in about 60 countries. Teva's
branded businesses focus on CNS, oncology, pain, respiratory and women's
health therapeutic areas as well as biologics. Teva currently employs
approximately 46,000 people around the world and reached $20.3 billion
in net revenues in 2012.
Teva Pharmaceutical Industries Ltd.
C. Mannix, 215-591-8912
Kristen Frank, 215-591-8908
Amitai, 972 (3) 926-7656
Vismunski-Weinberg, 972 (3) 926-7687